Neurofibromatosis Type 1 and Cosmetic Surgery: Removing Skin Neurofibromas, Café-au-Lait Lasers, Breast Screening, Blood Pressure, and the Plexiform Question

She is 38 and counts them sometimes, the way other people count gray hairs. There were a handful at twenty. There were dozens after her second pregnancy. Now there are well over a hundred small, soft, flesh-colored bumps scattered across her torso, a cluster along her bra line that catches on every strap, and a few on her neck and face that strangers glance at a beat too long. She was diagnosed with neurofibromatosis type 1 as a child because of the brown patches on her back. Her neurologist sees her once a year and asks about headaches and vision. Nobody has ever asked her how she feels about her skin. She books a consultation to ask whether any of this can come off.

That question deserves a real answer, and it is more answerable than many people with NF1 have been told. Neurofibromatosis type 1 and cosmetic surgery are not at odds. The bumps that bother people most are benign, removable, and very often removed. But NF1 is a whole-body condition, and a surgeon who treats it as a skin problem alone can miss the blood pressure issue that complicates anesthesia, the breast cancer risk that changes how breast surgery is planned, and the deeper tumor that should never be shaved off in an office.

Neurofibromatosis type 1 and cosmetic surgery: what the diagnosis actually is

The short answer: NF1 is a common inherited condition caused by changes in the NF1 gene that produces café-au-lait spots, freckling in skin folds, and benign nerve sheath tumors called neurofibromas, and for elective surgery the key distinction is between the small cutaneous neurofibromas on the skin and the larger plexiform neurofibromas underneath it.

NF1 affects roughly 1 in 3,000 people worldwide, which makes it one of the more common single-gene conditions a plastic surgeon will meet. It follows an autosomal dominant pattern, so an affected parent has a 50 percent chance of passing it on, yet about half of all cases arise from a brand-new genetic change with no family history. The gene makes neurofibromin, a protein that acts as a brake on cell growth signals. When it does not work properly, certain cells grow where they normally would not.

The revised international diagnostic criteria, updated in 2021, list a set of features and require two or more (or one, if a parent already has NF1):

• Six or more café-au-lait macules, flat light-brown patches larger than about 5 millimeters before puberty or 15 millimeters after.
• Freckling in the armpits or groin, small clustered spots in places the sun rarely reaches.
• Two or more neurofibromas of any type, or one plexiform neurofibroma.
• Lisch nodules or choroidal abnormalities, harmless spots on the iris or the back of the eye seen on an eye exam.
• An optic pathway glioma, a usually slow-growing tumor along the optic nerve, most often found in childhood.
• A distinctive bone finding, such as sphenoid wing dysplasia around the eye socket or bowing of the lower leg bone.
• A confirmed pathogenic NF1 gene variant.

For cosmetic purposes, the two kinds of neurofibroma behave so differently that they almost deserve different names. Cutaneous neurofibromas are the small, soft, dome-shaped or pedunculated bumps in the skin. They usually begin to appear around puberty, increase in number through adulthood, often surge during pregnancy, and can number in the hundreds or thousands. They are benign and, in the medical literature, essentially never turn malignant. Plexiform neurofibromas grow along larger nerves, often from birth or early childhood, and can be deep, extensive, and highly vascular. Around 30 to 50 percent of people with NF1 have at least one, many of them internal and only visible on imaging. They are also the tumors that, rarely, transform into a cancer called malignant peripheral nerve sheath tumor.

The condition varies enormously even within a family. One parent can have a few café-au-lait spots and a dozen bumps while their child has a facial plexiform tumor. That variability is why the consultation needs to start with the specific person's history rather than with the label.

NF1 is not a single problem a surgeon can read off a chart. The earlier piece on Marfan syndrome and cosmetic surgery and the piece on Turner syndrome made the same point about other genetic conditions: the visible feature is the reason for the visit, and the invisible features decide how the visit should go.

Removing cutaneous neurofibromas: excision, laser, and electrodesiccation

The short answer: cutaneous neurofibromas can be removed by surgical excision, CO2 laser vaporization, or electrodesiccation, each removed bump typically stays gone, new ones will keep appearing over time, and the realistic goal is reducing burden and fixing the ones that bother you most rather than clearing the skin for good.

This is the single most common reason adults with NF1 see a plastic surgeon or dermatologist, and it is legitimate in every sense. Surveys of adults with NF1 consistently rank visible cutaneous neurofibromas as one of the biggest drivers of reduced quality of life, ahead of many of the internal complications doctors spend more time on. The bumps itch, catch on clothing and jewelry, bleed when scratched, and draw attention that most people did not ask for.

The options fall into three families:

• Surgical excision. The bump is cut out with a scalpel and the skin closed with stitches. This gives the most precise result and a full specimen for the pathologist, and it suits larger lesions, lesions on the face, and any bump that looks or feels different from the rest. The trade-off is a linear scar for each one and a practical ceiling on how many can be done in a session. The approach is the same one covered in the piece on cosmetic mole removal, shave versus excision.
• CO2 laser vaporization. The laser removes the bump layer by layer. It works well for many small or medium lesions in one sitting, often under general anesthesia when the count runs into the hundreds. Healing leaves small round marks that are often slightly depressed or lighter than the surrounding skin, which is why the explainer on ablative versus non-ablative laser resurfacing is useful background on how these wounds behave.
• Electrodesiccation and related energy devices. An electrical current destroys the tissue, and published series from NF1 centers describe treating hundreds of small neurofibromas in a single session under anesthesia. Results resemble the laser approach: quick, efficient, with small textured or pale scars.

What to expect, honestly:

• A treated bump rarely comes back in the same spot, but the condition keeps producing new ones elsewhere. Plan on maintenance sessions every few years rather than a one-time clean slate.
• Scars are a trade, not an erasure. A flat white mark is usually less noticeable than a raised bump, but it is still a mark. On darker skin tones, pigment changes after laser or electrodesiccation are more likely, and test spots make sense. The guide to scar care after plastic surgery applies here as it does anywhere.
• Count and location drive the anesthesia plan. A dozen bumps can be done under local in an office. Two hundred across the torso usually means a general anesthetic in an accredited facility.
• Small neurofibromas look like other things. Skin tags, soft moles, and benign growths are often confused with them, which the piece on seborrheic keratoses and skin tags walks through. On the breast, areolar neurofibromas are common in women with NF1 and are sometimes mistaken for the glands described in the piece on Montgomery glands and areola bumps.

There is also a medical frontier worth knowing about. Drugs called MEK inhibitors block the growth pathway neurofibromin normally restrains. The FDA approved selumetinib in 2020 for children with symptomatic plexiform neurofibromas that cannot be fully removed, and approved mirdametinib in 2025 for both adults and children with that same problem. Topical MEK inhibitor gels aimed specifically at cutaneous neurofibromas are being tested in clinical trials. None of these is a cosmetic treatment today, but a patient taking an oral MEK inhibitor for a plexiform tumor has a medication that can cause skin rashes, nail-fold infections, and effects on the heart and eyes, and the prescribing team should be part of any elective surgical plan.

"A treated neurofibroma usually stays gone. The condition that made it does not. Good NF1 skin care is maintenance, and anyone selling a one-time cure is selling something else."

Café-au-lait spots, freckling, and the limits of lasers

The short answer: pigment lasers can lighten café-au-lait spots, but results in NF1 are inconsistent, the color often returns within months, and a test patch plus realistic expectations should come before any full treatment.

Café-au-lait macules are usually the first sign of NF1, and they matter less to most adults than the neurofibromas. But a large patch on the face, neck, or chest can be a reason for a consultation, and laser treatment comes up quickly.

The evidence is humbling. Q-switched and picosecond lasers target melanin and can lighten café-au-lait spots, sometimes dramatically. But studies report wide variation: some patches clear, some lighten partially, and a substantial share repigment within months, sometimes darker or patchier than before. Patches with jagged, irregular borders (more typical of conditions like McCune-Albright syndrome) have been reported to respond somewhat better than the smooth-edged "coast of California" patches typical of NF1, though no rule holds every time. The earlier piece on nevus of Ota, Hori nevus, and café-au-lait spots covers the laser mechanics in detail, and the overview of lasers for sun spots and pigmentation explains why pigment that sits at different depths behaves differently.

A sensible approach:

• Treat one test area first and wait at least two to three months to see whether the color stays down.
• Protect from sun before and after, because ultraviolet exposure drives repigmentation.
• Accept partial lightening as a reasonable result. Complete, permanent clearance is the exception.
• Consider camouflage. Cosmetic cover makeup works well on flat patches, and for some people the options described in the piece on scar camouflage and medical tattooing are worth discussing for stable, small areas.

Freckling in the armpits and groin rarely bothers people enough to treat. It is useful to the surgeon mainly as a diagnostic clue, and it does not change how incisions heal.

Plexiform neurofibromas, the face, and the lump that is not cosmetic

The short answer: plexiform neurofibromas are deeper, more vascular tumors that can distort the face, eyelid, or body and can bleed heavily during surgery, their treatment belongs with a team experienced in NF1, and a neurofibroma that becomes newly painful, grows quickly, or turns hard needs urgent evaluation rather than a cosmetic appointment.

Plexiform neurofibromas are where NF1 surgery stops being a dermatology procedure. On the face, a plexiform tumor around the eye can cause a drooping, thickened upper eyelid, a displaced eye, and asymmetry of the cheek and brow, sometimes combined with a defect in the bone of the eye socket. On the body, a diffuse plexiform tumor can create a soft, sagging mass of skin over the trunk, buttock, or limb that looks like loose skin and is anything but.

Several features make these operations different:

• Bleeding. Plexiform neurofibromas contain abnormal, fragile vessels, and blood vessel walls throughout the body can be weaker in NF1. Debulking a large tumor can cause substantial blood loss, so experienced teams plan for transfusion and sometimes block feeding vessels with embolization beforehand. The general principles in the piece on bleeding disorders and cosmetic surgery and the piece on hematoma after facelift are relevant, but plexiform surgery is a level beyond either.
• Incomplete removal is the norm. Because these tumors wrap around nerves, surgeons usually reduce them rather than remove them entirely, and regrowth is common, especially in younger patients. Many people have several debulking operations over a lifetime.
• Eyelid and facial work is reconstructive. A drooping lid from a plexiform tumor is not the same problem as age-related ptosis, a distinction the piece on eyelid ptosis versus blepharoplasty introduces. Repairs often combine tumor debulking, lid suspension, and later refinements, and the piece on facial and breast asymmetry covers the expectations that come with correcting an uneven face in stages.
• Insurance often applies. Removal of plexiform tumors and of neurofibromas that bleed, hurt, or obstruct vision is frequently considered medically necessary. The guide to when insurance covers plastic surgery explains the documentation that helps.

Then there is the warning that matters more than anything else in this piece. People with NF1 have a lifetime risk of malignant peripheral nerve sheath tumor that published estimates place at roughly 8 to 13 percent, usually arising in a plexiform neurofibroma or an atypical nodular tumor. The warning signs are:

• New, persistent, or worsening pain in a known neurofibroma, especially pain that wakes you at night.
• Rapid growth of a lump over weeks to months.
• A change from soft to hard.
• New weakness, numbness, or tingling in the area the nerve supplies.

Any of these calls for prompt evaluation at an NF1 clinic, usually with MRI and sometimes PET imaging, before anyone cuts. A lump with these features should never be shaved, lasered, or removed piecemeal for appearance. And every excised neurofibroma that looks unusual should go to pathology, as the piece on the pathology report after cosmetic surgery explains.

Blood pressure, anesthesia, and breast surgery with NF1

The short answer: before a general anesthetic, adults with NF1 should have blood pressure checked carefully and should be screened for pheochromocytoma if they have high blood pressure or symptoms, spinal tumors can affect epidurals and spinals, and women considering breast surgery need a plan that fits the earlier and more intensive breast screening NF1 calls for.

The preoperative side of NF1 is where the stakes climb from scars to safety.

Blood pressure. High blood pressure is more common in NF1 and can appear at a young age. Most cases are ordinary essential hypertension, but some come from narrowing of the kidney arteries, part of the vascular changes NF1 can cause, and a small share come from a pheochromocytoma, an adrenal tumor that releases surges of adrenaline. Studies estimate pheochromocytoma occurs in somewhere between about 0.1 and 5.7 percent of people with NF1, far above the general population. An undiagnosed pheochromocytoma under anesthesia can trigger a dangerous spike in blood pressure and heart rhythm problems. Screening is a straightforward blood or urine test for metanephrines. Anyone with NF1 who has high blood pressure, episodes of pounding headache, sweating, and palpitations, or blood pressure that swings unpredictably should have that test before an elective operation, and many anesthesiologists prefer to check regardless. The piece on high blood pressure before cosmetic surgery covers the general rules about readings and medications.

Anesthesia details. A few NF1-specific points belong in the anesthesia conversation, which the piece on anesthesia choice and the operative plan frames more broadly:

• Spinal neurofibromas can sit near the spinal cord or nerve roots. Before an epidural or spinal anesthetic, the team may want imaging of the spine.
• Scoliosis is common in NF1 and occasionally severe. The piece on scoliosis and cosmetic surgery explains how a curved spine affects positioning and body contouring.
• Airway tumors in the tongue, throat, or neck are uncommon but possible, and a history of voice change or swallowing trouble should be mentioned.
• Seizure disorders occur more often in NF1, and the medication timing rules in the piece on epilepsy and cosmetic surgery apply.
• Older reports described unusual responses to some muscle relaxants in NF1. The evidence is inconsistent, but the anesthesiologist should know the diagnosis and monitor accordingly.

Breast surgery and screening. Women with NF1 have a meaningfully higher risk of breast cancer before age 50, with studies reporting a risk several times that of the general population in that age group, and higher rates of aggressive tumor types. National guidelines now recommend that women with NF1 begin annual mammography at 30 and consider adding breast MRI from 30 to 50. Neurofibromas on the breast skin can also clutter a mammogram, which is one reason MRI helps. For anyone considering augmentation, reduction, or a lift, that means:

• Get up to date on screening before surgery, so a baseline exists and nothing suspicious is waiting to be found later.
• Discuss implant placement and imaging. Implants do not prevent screening, but they change how it is done. A surgeon who knows the screening plan can choose an approach that keeps imaging practical.
• Send reduction and lift tissue to pathology. The logic is the same as in the piece on family history of breast cancer, BRCA, and cosmetic breast surgery.
• Plan for areolar and breast-skin neurofibromas. They can be removed during the same operation, often through the planned incisions, which is a genuine advantage of combining procedures.

Wound healing. Most incisions in people with NF1 heal normally. New neurofibromas can occasionally appear in or near scars over the years, but there is no strong evidence that surgery itself causes widespread new tumors. The fact that a body contouring procedure crosses skin with neurofibromas is a reason to plan which bumps to excise along the way, not a reason to avoid the operation.

The person behind the chart. Learning disabilities and attention problems affect roughly half of people with NF1, and some adults appreciate written instructions, extra time in consultations, and a support person at follow-ups. The emotional side matters too. Living with visible tumors can shape how someone sees their own body for decades, and the piece on emotional recovery after plastic surgery is worth reading before surgery, not only after. For teenagers with NF1 who want bumps removed, the considerations in the piece on cosmetic surgery for teenagers apply, along with the reality that new neurofibromas tend to keep arriving through the late teens and twenties.

The honest summary

Neurofibromatosis type 1 is common, highly variable, and far more treatable on the skin than many adults with it have been led to believe. Cutaneous neurofibromas are benign, can be removed by excision, laser, or electrodesiccation, and removing them often improves quality of life in ways that matter. The limits are real: new bumps keep coming, every treated spot leaves some mark, and café-au-lait lasers are a coin flip with a test patch attached.

The rest of NF1 is why the choice of surgeon matters. Plexiform neurofibromas bleed, regrow, and belong with an experienced team. A neurofibroma that suddenly hurts, grows, or hardens is a medical question first. Blood pressure deserves a careful look, with pheochromocytoma screening before general anesthesia when there is any hint of it. And women with NF1 considering breast surgery should fold it into the earlier screening schedule the condition calls for, with every piece of removed tissue going to a pathologist.

If the first surgeon you see talks only about the bumps, it is worth a second consultation. The right plan treats the skin you want changed and accounts for everything underneath it.